#USA #Los Angeles #Schall Law Firm #Securities Fraud #Regeneron Pharmaceuticals

Opportunity for Regeneron Investors

On March 7, 2025, the Schall Law Firm, a prominent national firm specializing in shareholder rights litigation, announced an important opportunity for investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The firm is currently leading a class action lawsuit concerning significant alleged violations of federal securities laws by Regeneron.

Background of the Lawsuit

The lawsuit targets actions that occurred between November 2, 2023, and October 30, 2024, during which investors are encouraged to come forward. The central allegations suggest that Regeneron made false and misleading statements regarding its operations and the pricing structure of its leading drug, Eylea. Specifically, the complaint states that Regeneron paid credit card fees to its distributors under the condition that these distributors would not impose additional charges on Eylea customers for credit card transactions. This arrangement effectively subsidized the selling price of Eylea and misled investors regarding the drug’s market performance.

Implications of Misrepresentation

These concessions allegedly provided Regeneron a competitive edge, inflating Eylea's sales figures and misleading shareholders about the company’s performance. Furthermore, the lawsuit claims that the company violated the False Claims Act by overstating the Average Selling Price (ASP) for Eylea, which directly impacts how profits and returns are communicated to investors. When the actual circumstances became public, following revelations of these discrepancies, Regeneron’s stock value suffered, resulting in significant financial losses for many investors.

Joining the Class Action

Investors who suffered losses during this class period are now faced with a pivotal decision. The Schall Law Firm is inviting affected shareholders to join the class action before the deadline on March 10, 2025. Those interested should reach out directly to the firm to discuss their rights in this matter without any obligation or cost.

Brian Schall, a representative of the firm, emphasized the importance of holding companies accountable for their statements and operations. The ability for investors to reclaim losses hinges on participating in such legal actions, particularly when companies might have misled their shareholder base.

Shareholders who choose not to participate may remain as absent class members and lose out on potential recovery of their investments. Interested parties can contact the Schall Law Firm at their Los Angeles office or through their website for more details on how to proceed.

Conclusion

As the lawsuit progresses, it represents not only a crucial opportunity for affected Regeneron investors but also a significant movement toward greater accountability in corporate practices within the pharmaceutical industry. Investors are urged to take action to ensure their voice is heard and their rights are protected in what may be a transformative legal battle for the company and its stakeholders.

For detailed inquiries or to participate, investors can reach out to the Schall Law Firm at:

• - Phone: 310-301-3335
• - Website: schallfirm.com
• - Email: info@schallfirm.com

This lawsuit could serve as a landmark case in securities litigation, illustrating the critical role that transparency and accuracy play in protecting investors in the financial markets.